keyword
MENU ▼
Read by QxMD icon Read
search

Denosumab

keyword
https://www.readbyqxmd.com/read/29782843/role-of-nutritional-vitamin-d-in-osteoporosis-treatment
#1
REVIEW
Yi-Chou Hou, Chia-Chao Wu, Min-Tser Liao, Jia-Fwu Shyu, Chi-Feng Hung, Tzung-Hai Yen, Chien-Lin Lu, Kuo-Cheng Lu
Osteoporosis is a systemic skeletal disorder characterized by a decrease in bone mass and microarchitectural deterioration of bone tissue. The World Health Organization has defined osteoporosis as a decrease in bone mass (50%) and bony quality (50%). Vitamin D, a steroid hormone, is crucial for skeletal health and in mineral metabolism. Its direct action on osteoblasts and osteoclasts and interaction with nonskeletal tissues help in maintaining a balance between bone turnover and bone growth. Vitamin D affects the activity of osteoblasts, osteoclasts, and osteocytes, suggesting that it affects bone formation, bone resorption, and bone quality...
May 18, 2018: Clinica Chimica Acta; International Journal of Clinical Chemistry
https://www.readbyqxmd.com/read/29778323/is-there-a-flare-phenomenon-on-bone-scintigraphy-in-men-with-advanced-prostate-cancer-treated-with-radium-223
#2
Gesa Isensee, Anne Péporté, Joachim Müller, Sabine Schmid, Silke Gillessen, Aurelius Omlin
INTRODUCTION: Radium-223 is an approved survival-prolonging treatment option in men with castration-resistant prostate cancer (mCRPC) and bone metastases. In the registration trial (ALSYMPCA), no regular imaging was mandated. We aimed to analyze men with metastatic mCRPC treated with radium-223 who had bone scintigraphy for staging and treatment monitoring. PATIENTS AND METHODS: Retrospective chart review was performed of mCRPC patients who received 6 cycles of radium-223 and who underwent bone scintigraphy before start of radium-223 and after 3 and 6 cycles of treatment...
April 23, 2018: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/29774416/restoration-of-proximal-periprosthetic-bone-loss-by-denosumab-in-cementless-total-hip-arthroplasty
#3
Satoshi Nagoya, Kenji Tateda, Shunichiro Okazaki, Ima Kosukegawa, Junya Shimizu, Toshihiko Yamashita
Denosumab contributed to the restoration of proximal periprosthetic bone loss around the femoral stem that were measured using a DEXA, especially in zone 7, at 1 year after cementless THA in elderly osteoporotic patients. INTRODUCTION: Although bone quality is an important issue in elderly osteoporotic patients who underwent total hip arthroplasty (THA) with a cementless stem, periprosthetic bone mineral density (BMD) in the proximal femur has been reported to be decreased by 15-40% postoperatively...
May 17, 2018: European Journal of Orthopaedic Surgery & Traumatology: Orthopédie Traumatologie
https://www.readbyqxmd.com/read/29771348/letter-to-the-editor-effects-of-long-term-denosumab-on-bone-histomorphometry-and-mineralization-in-women-with-postmenopausal-osteoporosis
#4
Toshihiro Sugiyama
No abstract text is available yet for this article.
May 15, 2018: Journal of Clinical Endocrinology and Metabolism
https://www.readbyqxmd.com/read/29765223/efficacy-of-denosumab-in-two-cases-with-multiple-system-atrophy-and-osteoporosis
#5
Masashi Uehara, Yukio Nakamura, Jun Takahashi, Takako Suzuki, Hiroyuki Kato
Background: Multiple-system atrophy (MSA) is an α-synucleinopathy with a very aggressive course and poor prognosis, which lacks efficient treatment. Thus, MSA represents a serious health and social problem. Progressive stridor and acute laryngeal obstruction likely occur in MSA; however, little is known about the bone metabolism or efficacy of bone absorption drugs, such as denosumab, in osteoporosis with MSA. Case presentation and methods: Two male patients with osteoporosis in MSA presented to our institution (at 54 and 68 years of age)...
2018: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/29755856/the-guiding-role-of-bone-metabolism-test-in-osteoporosis-treatment
#6
REVIEW
Wei Zhang, Guo-Ji Yang, Shi-Xian Wu, Dong-Qing Li, Ying-Bo Xu, Cheng-Hong Ma, Jun-Ling Wang, Wei-Wen Chen
Osteoporosis (OP) and osteoporotic fractures are becoming a serious health care issue in the world. Calcium and vitamin D are the basic treatment for osteoporosis. Nonetheless, they do not effectively reduce the incidences of fracture. Currently approved treatments for osteoporosis include selective estrogen receptor modulators (SERMs), bisphosphonates, denosumab, teriparatide, calcitonin and others. However, the appearance of some adverse effects including atypical fracture and breast cancer has limited long-term treatments above mentioned...
2018: American Journal of Clinical and Experimental Immunology
https://www.readbyqxmd.com/read/29753381/denosumab-associated-severe-hypocalcemia-in-a-patient-with-chronic-kidney-disease
#7
REVIEW
Sohail Abdul Salim, Lakshmi Ramachandran Nair, Litty Thomas, Vishnu Garla, Venkataraman Palabindala, Mohit Agarwal, Tibor Fülöp
Denosumab is a monoclonal antibody directed against the receptor activator of nuclear factor kappa B ligand (RANKL). Denosumab has been shown to reduce the risk of skeletal-related events, including spinal cord compression, pathologic fracture and hypercalcemia of malignancy in patients with bone metastases. Hypocalcemia is a known side effect of denosumab, occurring in an estimated 8-14% of the patients. Here, we present an asymptomatic patient with stage-5 chronic kidney disease and severe hypocalcemia who had received denosumab 1 month earlier...
May 2018: American Journal of the Medical Sciences
https://www.readbyqxmd.com/read/29752458/denosumab-shows-promise-for-giop
#8
Sarah Onuora
No abstract text is available yet for this article.
May 11, 2018: Nature Reviews. Rheumatology
https://www.readbyqxmd.com/read/29750753/immune-checkpoint-inhibitor-anti-ctla-4-anti-pd-1-therapy-alone-versus-immune-checkpoint-inhibitor-anti-ctla-4-anti-pd-1-therapy-in-combination-with-anti-rankl-denosumuab-in-malignant-melanoma-a-retrospective-analysis-at-a-tertiary-care-center
#9
Muhammad Z Afzal, Keisuke Shirai
Denosumab is a monoclonal antibody against RANK ligand with a role in the prevention of skeletal-related events and is also known to possess antitumor properties. In this retrospective review, we aim to evaluate the synergist effect of a combination therapy with immune checkpoint inhibitors and denosumab in malignant melanoma patients. Patients of 18 years of age or older with a diagnosis of malignant melanoma who have received immune checkpoint inhibitors and denosumab between June 2015 and May 2017 were divided into two cohorts: cohort A (immune checkpoint inhibitors only) and cohort B (immune checkpoint inhibitors and denosumab)...
May 10, 2018: Melanoma Research
https://www.readbyqxmd.com/read/29745092/therapeutic-benefits-of-neoadjuvant-and-post-operative-denosumab-on-sacral-giant-cell-tumor-a-retrospective-cohort-study-of-30-cases
#10
Zhongyan Chen, Yi Yang, Wei Guo, Rongli Yang, Xiaodong Tang, Taiqiang Yan, Tao Ji, Lu Xie, Jie Xu, Jun Wang
PURPOSE: Denosumab, a new monoclonal antibody that inhibits receptor activator for nuclear factor Kβ ligand (RANKL), has recently been approved by FDA for the treatment of aggressive giant cell tumor of bone (GCTB). So we initiated this study to evaluate the clinical benifits of denosumab used preoperatively or postoperatively. METHODS: Patients diagnosed with classic sacral GCT without metastasis were included in this study. Patients were assigned into 3 groups according to the use of denosumab: control group 1, post-operative group 2 and neoadjuvant group 3...
March 2018: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://www.readbyqxmd.com/read/29741702/prognosis-of-metastatic-giant-cell-tumor-of-bone-in-the-pre-denosumab-era-a-systematic-review-and-a-meta-analysis
#11
Boris Itkin, Samanta Straminsky, Gabriela De Ronato, Daniel Lewi, Adolfo Marantz, Ariel Bardach
Background: Data on long-term prognosis of metastatic GCT (mGCT) is scant. The frequency of spontaneous regressions (SRs) is unknown. We aimed to estimate the prognosis of mGCT. Methods: We searched electronic scientific literature databases and generic Internet from January 1980 to August 2017. After identifying eligible studies we performed descriptive analyses and meta-analyses to estimate overall survival (OS), disease specific survival (DSS) and frequency of SRs in the years before the widespread use of denosumab...
May 5, 2018: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29741296/assessment-and-management-of-bone-health-in-women-with-oestrogen-receptor-positive-breast-cancer-receiving-endocrine-therapy-position-statement-of-the-endocrine-society-of-australia-the-australian-and-new-zealand-bone-mineral-society-the-australasian-menopause
#12
Mathis Grossmann, Sabashini Ramchand, Frances Milat, Amanda Vincent, Elgene Lim, Mark A Kotowicz, Jill Hicks, Helena Teede
OBJECTIVE: To formulate clinical consensus recommendations on bone health assessment and management of women with oestrogen receptor-positive early breast cancer receiving endocrine therapy. METHODS: Representatives appointed by relevant Australian Medical Societies used a systematic approach for adaptation of guidelines (ADAPTE) to derive an evidence-informed position statement addressing five key questions. RESULTS: Women receiving adjuvant aromatase inhibitors and the subset of premenopausal woman on tamoxifen have accelerated bone loss and increased fracture risk...
May 9, 2018: Clinical Endocrinology
https://www.readbyqxmd.com/read/29731457/-diagnosis-and-treatment-of-rheumatoid-arthritis-toward-the-best-practice-anti-bone-resorbing-treatment-for-rheumatoid-arthritis
#13
Yoshiya Tanaka
Rheumatoid arthritis(RA)is a systemic inflammatory disease characterized by chronic synovitis and bone damage. The imbalance in immune system and its mediated chronic inflammation result in pathological processes such as joint destruction as well as secondary osteoporosis. Proinflammatory cytokines such as TNF and IL-6 cause an imbalance in bone metabolism via direct and/or indirect effects on osteoclasts. However, biologic DMARDs targeting TNF and IL-6 have revolutionized the treatment of RA, producing significant improvements in clinical and structural outcomes that were not previously observed...
2018: Clinical Calcium
https://www.readbyqxmd.com/read/29727238/treatment-of-osteoporosis-whom-how-and-for-how-long
#14
Anastasia D Dede, Margaret Callan
Identification of patients at risk for fragility fractures is the first important step in the management of osteoporosis. Bisphosphonates have been the mainstay of treatment for decades, whereas denosumab and selective oestrogen receptor modulators are other available licensed antiresorptive drugs. Currently teriparatide is the only approved anabolic agent in Europe, while abaloparatide and romosozumab are awaiting approval and might be available in the near future. For bisphosphonates, current guidance suggests an initial treatment course of 3-5 years and more prolonged treatment should be pursued in patients with higher fracture risk...
May 2, 2018: British Journal of Hospital Medicine
https://www.readbyqxmd.com/read/29725863/persistence-of-and-switches-from-teriparatide-treatment-among-women-and-men-with-osteoporosis-in-the-real-world-a-claims-database-analysis
#15
Tomoko Usui, Masaru Funagoshi, Kahori Seto, Kazuki Ide, Shiro Tanaka, Koji Kawakami
This study investigated the real-world persistence rate and switches of teriparatide-treated patients using a claims database in Japan. The persistence rate of teriparatide at 12 months was 34.9%, and approximately one-third of the patients were not treated with any osteoporosis drugs after teriparatide. Improvement in persistence and switches are desired. PURPOSE: We aimed to elucidate the persistence rates and switches before and after teriparatide treatment in real-world osteoporosis patients based on data from a medical claims database in Japan...
May 3, 2018: Archives of Osteoporosis
https://www.readbyqxmd.com/read/29721807/potential-association-with-early-changes-in-serum-calcium-level-after-starting-or-switching-to-denosumab-combined-with-eldecalcitol
#16
Tsuyoshi Asano, Tomohiro Shimizu, Daisuke Takahashi, Masahiro Ota, Dai Sato, Hiroki Hamano, Shigeto Hiratsuka, Masahiko Takahata, Norimasa Iwasaki
The aims of this study are to investigate changes in serum calcium (Ca) level after switching from either non-therapy, bisphosphonate, selective estrogen receptor modulators (SERM) or teriparatide treatments to a combination therapy of denosumab (DMAb), and eldecalcitol, and the association between early changes in serum calcium and changes in bone metabolic markers and bone mineral density (BMD). 129 patients with postmenopausal osteoporosis (32 non-pretreatment, 50 bisphosphonates, 18 SERM, and 29 teriparatide) were recruited and switched to DMAb plus eldecalcitol...
May 2, 2018: Journal of Bone and Mineral Metabolism
https://www.readbyqxmd.com/read/29720961/osteoporosis-therapy-with-denosumab-in-organ-transplant-recipients
#17
Jana Brunova, Simona Kratochvilova, Jitka Stepankova
Objective: Osteoporosis and fragility fractures represent serious complications for the solid organ transplant population. The recommended osteoporosis therapy for organ recipients involves supplementation with calcium and vitamin D and bisphosphonate administration. However, these options can prove limited for patients with impaired renal function. An alternative therapy option is offered by denosumab, a monoclonal antibody that targets receptor activator of nuclear factor kappa-B ligand...
2018: Frontiers in Endocrinology
https://www.readbyqxmd.com/read/29720299/effects-of-denosumab-after-treatment-discontinuation-a-review-of-the-literature
#18
Maryam Iranikhah, Crystal Deas, Pilar Murphy, Maisha Kelly Freeman
OBJECTIVE: To review and summarize studies on the effects of denosumab on bone mineral density following the discontinuation of therapy. DATA SOURCES: A search of PubMed (1966-July 2017) and International Pharmaceutical Abstracts (1970-July 2017) was conducted using the Medical Subject Headings (MeSH) terms denosumab, osteoporosis, and withholding treatment in combination with free term searches including the words drug holiday, discontinue, discontin*, and drug discontinuation...
March 1, 2018: Consultant Pharmacist: the Journal of the American Society of Consultant Pharmacists
https://www.readbyqxmd.com/read/29713913/osteonecrosis-of-the-jaw-in-patients-transitioning-from-bisphosphonates-to-denosumab-treatment-for-osteoporosis
#19
P J Voss, D Steybe, P Poxleitner, R Schmelzeisen, C Munzenmayer, H Fuellgraf, A Stricker, W Semper-Hogg
Antiresorptive-related osteonecrosis of the jaw (ARONJ) is a rare but severe side effect of antiresorptive treatment with bisphosphonates or RANKL-antibody denosumab in patients with malignant diseases or osteoporosis. Whilst osteonecrosis of the jaw (ONJ) related to the administration of bisphosphonates (BPs) has been investigated for more than 1 decade now, only few data are available on denosumab-related ONJ, especially in patients with osteoporosis. From 2008 to 2016, 52 osteoporosis patients were treated with ARONJ in the Department of Oral and Maxillofacial Surgery, University Medical Center Freiburg, Germany...
April 30, 2018: Odontology
https://www.readbyqxmd.com/read/29713798/hypocalcemia-and-bone-mineral-density-changes-following-denosumab-treatment-in-end-stage-renal-disease-patients-a-meta-analysis-of-observational-studies
#20
REVIEW
C Thongprayoon, P Acharya, C Acharya, J Chenbhanich, T Bathini, B Boonpheng, K Sharma, K Wijarnpreecha, P Ungprasert, M L Gonzalez Suarez, W Cheungpasitporn
The incidence of hypocalcemia and bone mineral density (BMD) changes in end-stage renal disease (ESRD) patients on denosumab remains unclear. We performed this meta-analysis to assess the incidence of denosumab-associated hypocalcemia and effects of denosumab on BMD in ESRD patients. A literature search was conducted using MEDLINE, EMBASE, and Cochrane Database from inception through November 2017 to identify studies evaluating incidence of denosumab-associated hypocalcemia and changes in serum calcium, phosphate, alkaline phosphatase (ALP), parathyroid hormone (PTH), and BMD from baseline to post-treatment course of denosumab in ESRD patients...
April 30, 2018: Osteoporosis International
keyword
keyword
8329
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"